SPRAY, METERED;NASAL - 0.137MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SPRAY, METERED;NASAL - 0.137MG/SPRAY;0.05MG/SPRAY, SOLUTION/DROPS;OPHTHALMIC - 0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SPRAY, METERED;NASAL - 0.137MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Polpharma is a Poland-based CDMO and API producer. With over 70 years of experience, it is Poland's bigge...
Polpharma is a Poland-based CDMO and API producer. With over 70 years of experience, it is Poland's biggest API manufacturer. It provides its customers with materials ranging from clinical quantities up to market supply. Polpharma has fully integrated all of its operations, from R&D to manufacturing, leveraging all its key competencies to deliver cost-effective and on-time solutions to its customers. It manufactures APIs at a cGMP-compliant and FDA-approved multipurpose plant. It has invested US$ 45 million to expand its API plant in Starogard Gdanski to include HPAPI and cryogenic technologies, as well as a pilot plant and R&D capabilities.
Kalintis Healthcare is a vision with a drive to create a health-conscious Pharmaceuticals Company serving...
Kalintis Healthcare is a vision with a drive to create a health-conscious Pharmaceuticals Company serving to bring Wellness to Humanity. We develop robust in-house technology by setting the highest quality standards for the manufacturing of Speciality Chemicals, Advanced Intermediates, and Active Pharmaceutical Ingredients in our Chemical Process R&D and subsequently execute the Commercial-scale manufacturing in order to serve global customers. The APIs manufactured are targeted for the USA market & the rest all products targeted for global supplies. Plans are in place to file atleast three DMF’s in a year.